SCHEMBL798464

SCHEMBL798464

C=Cc1cc(NC(=O)OC(C)(C)C)ncn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.40
GSK3B P49841 1/20 0.40
DYRK1A Q13627 1/20 0.40
MAP4K4 O95819 1/20 0.39
AAK1 Q2M2I8 2/20 0.38
MKNK2 Q9HBH9 1/20 0.36
ATR Q13535 1/20 0.36
SYK P43405 1/20 0.35
SCN9A Q15858 1/20 0.34
CDK1 P06493 1/20 0.34
EGLN2 Q96KS0 1/20 0.33
PRMT1 Q99873 1/20 0.33
EGFR P00533 1/20 0.33
SRC P12931 1/20 0.33
CYP17A1 P05093 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
MAP2K7 O14733 1/20 0.33
MAPK1 P28482 1/20 0.33
AURKA O14965 1/20 0.33
RPS6KB1 P23443 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL798703 0.87 L3MBTL1 (0.41) L3MBTL1GSK3BDYRK1AMAP4K4AAK1
SCHEMBL29070848 0.83 KDM4E (0.41) L3MBTL1GSK3BDYRK1AMAP4K4AAK1
SCHEMBL29070845 0.83 KDM4E (0.41) L3MBTL1GSK3BDYRK1AMAP4K4AAK1
SCHEMBL17362852 0.80 MKNK2 (0.39) L3MBTL1GSK3BDYRK1AMAP4K4AAK1
SCHEMBL17362851 0.80 MKNK2 (0.39) L3MBTL1GSK3BDYRK1AMAP4K4AAK1
SCHEMBL18805592 0.79 L3MBTL1 (0.68) L3MBTL1GSK3BDYRK1AMAP4K4AAK1
SCHEMBL18805591 0.79 ATR (0.45) L3MBTL1GSK3BDYRK1AMAP4K4AAK1
SCHEMBL19890987 0.79 L3MBTL1 (0.44) L3MBTL1GSK3BDYRK1AMAP4K4AAK1
SCHEMBL29400652 0.79 ATR (0.45) L3MBTL1GSK3BDYRK1AMAP4K4AAK1
SCHEMBL18814953 0.79 L3MBTL1 (0.49) L3MBTL1GSK3BDYRK1AMAP4K4AAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240092799-A1 MNK INHIBITORS HEPAGENE THERAPEUTICS HK LTD (CN) 2024-03-21 US disclosed
CN-116490505-A MNK inhibitors 和博医药有限公司 2023-07-25 CN disclosed
EP-4200296-A1 MNK INHIBITORS Hepagene Therapeutics (HK) Limited (HK) 2023-06-28 EP disclosed
WO-2022038563-A1 MNK INHIBITORS Hepagene Therapeutics (HK) Limited (CN) 2022-02-24 WO disclosed
US-20140171408-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2014-06-19 US disclosed
US-8697708-B2 Azabenzothiazole compounds, compositions and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-04-15 US disclosed
EP-2616072-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F.HOFFMANN-LA ROCHE AG (CH) 2013-07-24 EP disclosed
US-20120202788-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed
WO-2012035039-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240092799-A1 MNK INHIBITORS MKNK1, MATK, NEK1 L3MBTL1 1524/4885GSK3B 1232/4885DYRK1A 1054/4885
US-20140171408-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F12, CHRM1, NPY1R L3MBTL1 3602/4885GSK3B 1300/4885DYRK1A 1465/4885
US-20120202788-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F12, CHRM1, NPY1R L3MBTL1 3602/4885GSK3B 1300/4885DYRK1A 1465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.